1st Patient Enrolls in Phase 2 Study of Oral Therapy, OPRX-106, for Ulcerative Colitis

1st Patient Enrolls in Phase 2 Study of Oral Therapy, OPRX-106, for Ulcerative Colitis
Protalix BioTherapeutics recently announced that the first patient has been enrolled in the Phase 2 clinical trial evaluating the safety, efficacy and properties of its lead drug candidate, OPRX-106, for the treatment ulcerative colitis (UC), the company announced in a press release. The proof of concept, randomized, open label Phase 2 study (NCT02768974) will evaluate the safety,  efficacy

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *